Cargando…

Syk Tyrosine Kinase and B Cell Antigen Receptor (BCR) Immunoglobulin-α Subunit Determine BCR-mediated Major Histocompatibility Complex Class II–restricted Antigen Presentation

Stimulation of CD4(+) helper T lymphocytes by antigen-presenting cells requires the degradation of exogenous antigens into antigenic peptides which associate with major histocompatibility complex (MHC) class II molecules in endosomal or lysosomal compartments. B lymphocytes mediate efficient antigen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lankar, Danielle, Briken, Volker, Adler, Kristin, Weiser, Peter, Cassard, Sylvanie, Blank, Ulrich, Viguier, Mireille, Bonnerot, Christian
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 1998
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213387/ https://www.ncbi.nlm.nih.gov/pubmed/9730884

Ejemplares similares

Type II and III Receptors for Immunoglobulin G (IgG) Control the Presentation of Different T Cell Epitopes from Single IgG-complexed Antigens
por: Amigorena, Sebastian, et al.
Publicado: (1998)

The riddle of lymphoma BCR-antigenes
por: Thurner, Lorenz, et al.
Publicado: (2018)

Dynamics of Major Histocompatibility Complex Class II Compartments during B Cell Receptor–mediated Cell Activation
por: Lankar, Danielle, et al.
Publicado: (2002)

The actin-based motor protein myosin II regulates MHC class II trafficking and BCR-driven antigen presentation
por: Vascotto, Fulvia, et al.
Publicado: (2007)

Modulation of BCR Signaling by the Induced Dimerization of Receptor-Associated SYK
por: Westbroek, Mark L., et al.
Publicado: (2017)

TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia
por: Zhang, Yan-Ru, et al.
Publicado: (2020)

Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma
por: Sonowal, Himangshu, et al.
Publicado: (2023)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
por: de Carvalho, Daiana Landenberger, et al.
Publicado: (2012)

Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation
por: Romero-Camarero, Isabel, et al.
Publicado: (2013)

Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization
por: Regnault, Armelle, et al.
Publicado: (1999)

Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia
por: Ferrer, Gerardo
Publicado: (2018)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase
por: Cuesta-Domínguez, Álvaro, et al.
Publicado: (2012)

BCR-ABL rearrangement and HLA antigens: a possible link to leukemia pathogenesis and immunotherapy
por: Giunta, Marina, et al.
Publicado: (2012)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

P1267: HSP110 FAVORS BCR SIGNALING THROUGH SYK PHOSPHORYLATION IN DIFFUSE LARGE B CELL LYMPHOMA
por: Cabaud Gibouin, V., et al.
Publicado: (2022)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

Early BCR Events and Antigen Capture, Processing, and Loading on MHC Class II on B Cells
por: Avalos, Ana M., et al.
Publicado: (2014)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

HAX1 deletion impairs BCR internalization and leads to delayed BCR-mediated apoptosis
por: Wolkerstorfer, Susanne, et al.
Publicado: (2016)

Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity
por: Sun, Yuhan, et al.
Publicado: (2022)

Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells
por: Purroy, Noelia, et al.
Publicado: (2016)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Components of the antigen processing and presentation pathway revealed by gene expression microarray analysis following B cell antigen receptor (BCR) stimulation
por: Lee, Jamie A, et al.
Publicado: (2006)

A model integrating tonic and antigen-triggered BCR signals to predict the survival of primary B cells
por: Yasuda, Shoya, et al.
Publicado: (2017)

The FcμR Limits Tonic BCR Signaling by Regulating IgM-BCR Expression
por: Nguyen, Trang T. T., et al.
Publicado: (2017)

Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma
por: Amato, Teresa, et al.
Publicado: (2016)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

The SNARE protein Vti1b is recruited to the sites of BCR activation but is redundant for antigen internalisation, processing and presentation
por: Music, Amna, et al.
Publicado: (2022)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Alternative end-joining in BCR gene rearrangements and translocations: Alternative end-joining in BCR gene rearrangements and translocations
por: Bai, Wanyu, et al.
Publicado: (2022)

NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
por: Niwa, Tomoko, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_mqd0oaifr4fj4tbh1kn4b3s3so